Targeted Therapies in Breast Cancer PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Targeted Therapies in Breast Cancer PDF full book. Access full book title Targeted Therapies in Breast Cancer by Gw Sledge. Download full books in PDF and EPUB format.
Author: Gw Sledge
Publisher: Clinical Pub
ISBN: 9781846920660
Category : Breast
Languages : en
Pages : 0
Get Book Here
Book Description
This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management.
Author: Gw Sledge
Publisher: Clinical Pub
ISBN: 9781846920660
Category : Breast
Languages : en
Pages : 0
Get Book Here
Book Description
This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management.
Author: Kelly K. Hunt
Publisher: Springer Science & Business Media
ISBN: 159745222X
Category : Medical
Languages : en
Pages : 469
Get Book Here
Book Description
The three sections of this volume present currently available cancer gene therapy techniques. Part I describes the various aspects of gene delivery. In Part II, the contributors discuss strategies and targets for the treatment of cancer. Finally, in Part III, experts discuss the difficulties inherent in bringing gene therapy treatment for cancer to the clinic. This book will prove valuable as the volume of preclinical and clinical data continues to increase.
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages : 77
Get Book Here
Book Description
During the last three years of support of the career development award, we sought to develop and evaluate recombinant adeno-associated virus vectors encoding anti- angiogenic factors. We have completed the work with significant outcome, and also initiated new studies that will allow us to test novel possibilities for breast cancer treatment. The outcome of the present studies strongly indicated that sustained expression of anti-angiogenic factors not only provide significant growth inhibition of localized cancer in mouse model but also exerted tumor-free survival in combination with chemotherapy. We have also identified that the effect of anti-angiogenic therapy with rAAV in combination with chemotherapy, was independent of surviving pathway. Histopathological analysis of major visceral organs and liver enzyme analysis also revealed no toxicity because of combination therapy.
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages : 14
Get Book Here
Book Description
We are developing methods to derive gene transfer vectors capable of accomplishing targeted gene delivery to metastatic breast cancer cells. In this regard, strategies have been explored to modify adenoviral vectors by altering their binding tropism. Genetic methods employed have allowed for the modification of the native adenoviral binding protein (fiber) to incorporate cancer-relevant cell-binding ligands. Immunologic methods have yielded an antifiber antibody which specifically ablates native adenoviral tropism and provides a site for the addition of breast cancer-relevant ligands. The results developed herein have allowed for the successful retargeting of the adenoviral vector via either the genetic or immunologic approach. In addition, targeted, tumor-specific gene delivery has been achieved in vitro. These methods will now allow the evaluation of these vector systems in in vivo models of human breast cancer. The utility of the vectors in this context will allow the development of gene therapy strategies for disseminated breast cancer.
Author: Wolfgang Walther
Publisher: Springer Science & Business Media
ISBN: 1592590861
Category : Medical
Languages : en
Pages : 633
Get Book Here
Book Description
Since the discovery of the molecular structure of genes and the unveiling of the molecular basis of numerous human diseases, scientists have been fas- nated with the possibility of treating certain diseases by transducing foreign DNA into the affected cells. Initially, it was proposed that the foreign DNA could either replace defective nonfunctional genes, or code for therapeutic proteins. This concept has evolved into the rapidly growing field of gene therapy. Even though surgery, radiotherapy, and chemotherapy are widely ava- able and routinely used for cancer treatment, these therapies fail to cure approximately 50 percent of cancer patients. Therefore, since it is a disease characterized by aberrant gene expression, cancer has been a target of gene therapy research since the inception of this treatment modality. Numerous cancer gene therapy strategies are currently being investigated, including gene replacement therapy, the regulation of gene expression to modulate immu- logical responses to tumors, the direct killing of tumor cells, and direct int- ference with tumor growth. In this context, gene transfer systems, tumor-specific expression vectors, and novel therapeutic genes have been extensively st- ied. All these strategies aim for the selective destruction of human malignant disease while circumventing the destruction of nonmalignant cells and tissues thereby minimizing toxicity to the patient.
Author: Harold J. Burstein
Publisher:
ISBN: 0199735670
Category : Medical
Languages : en
Pages : 61
Get Book Here
Book Description
The development of monoclonal antibodies and other inhibitors of specific molecules, fully utilizing the insights learned from molecular techniques such as comparative microarrays and protein expression patterns, has led to the development and FDA approval of several agents for the treatment of breast cancer, such as trastuzamab (Herceptin, targeting HER-2 positive tumors) and lapatinib (Tykerb, targeting tumors with mutated/overexpressed EGFR 1 and 2). Other agents specifically targeting the estrogen receptor, the aromatose pathway and microtubule dynamics, fulvestrant (Faslodex, targeting the ER specifically in breast cancer cells), and letrozole (Femara, targeting the aromatose pathway), raloxifene (Evista, a selective estrogen receptor modulator), ixabepilone (Ixempra, a ?-tubulin inhibitor) have also been approved for various stages and specific settings in breast cancer treatment. The current challenges in the field include further targeting of these agents as part of specific strategies for each patient (biomarker testing, pharmacogenetics, etc.), as well as follow-up and management of adverse events. Part of the Oxford American Pocket Notes series, this volume provides clinicians with the ultra-concise, evidence-based, current information and insight on implementing the latest treatment strategies, including targeted agents, into clinical practice. This portable volume is intended to provide quick, easily accessible guidance for the practicing oncologist, oncology care staff (including nurses and PAs) as well as the primary care practitioner, on the mechanism of action, dosing and administration and adverse effects of the approved targeted agents.
Author: David T. Curiel
Publisher: Springer Science & Business Media
ISBN: 1592597858
Category : Medical
Languages : en
Pages : 491
Get Book Here
Book Description
A complete introduction and guide to the latest developments in cancer gene therapy-from bench to bedside. The authors comprehensively review the anticancer genes and gene delivery methods currently available for cancer gene therapy, including the transfer of genetic material into the cancer cells, stimulation of the immune system to recognize and eliminate cancer cells, and the targeting of the nonmalignant stromal cells that support their growth. They also thoroughly examine the advantages and limitations of the different therapies and detail strategies to overcome obstacles to their clinical implementation. Topics of special interest include vector-targeting techniques, the lessons learned to date from clinical trials of cancer gene therapy, and the regulatory guidelines for future trials. Noninvasive techniques to monitor the extent of gene transfer and disease regression during the course of treatment are also discussed.
Author: Zodwa Dlamini
Publisher: Springer Nature
ISBN: 3031528603
Category :
Languages : en
Pages : 390
Get Book Here
Book Description
Author: Erlinda M. Gordon
Publisher: BoD – Books on Demand
ISBN: 1839694157
Category : Medical
Languages : en
Pages : 57
Get Book Here
Book Description
The revival of DeltaRex-G (formerly Rexin-G)—the first proactive tumor-hunting/tumor-killing biomedicine of this kind in history—returned active tumor surveillance and a precision-guided “silver bullet” (dnG1 killer gene) to the cancer clinic with “Expanded Access” in 2019. Empowered by US Right-to-Try legislation, while honoring ethical principles of “informed consent,” this unique graphic/picturesque presentation of clinical and translational medicine is intended for postmodern (post-Enlightenment) layman readers, including cancer patients, students, researchers, and future practitioners in the field of precision gene-based medicine. Confronting logical fallacies in popular opinion, the authors present newsworthy, up-to-date clinical research documenting the successful management of refractory metastatic cancers with tumor-targeted gene therapy vectors—validating “pathotropic” (disease-seeking) tumor targeting avant la lettre.
Author: Jenifer R. Prosperi
Publisher: Springer
ISBN: 3319701428
Category : Medical
Languages : en
Pages : 193
Get Book Here
Book Description
We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy.
